Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Shares of pharmaceutical companies declined after U.S. President Donald Trump announced plans to lower U.S. prescription drug ...

The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan ...

Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug ...

Shares of global pharma stocks slumped on Monday after President Trump vowed to cut drug prices for Americans by as much as 80%.

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...